Stay updated on Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.5%
    Check dated 2025-06-20T05:52:59.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.0%
    Check dated 2025-06-13T01:00:22.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T21:09:54.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    0.8%
    Check dated 2025-05-29T16:10:54.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-05-01T03:20:55.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the removal of detailed information about the PENELOPE-B study and its objectives, while adding new references to the study's collaborators and a new version revision. The focus has shifted towards the CDK 4/6 inhibitor treatment and its implications for breast cancer patients.
    Difference
    55%
    Check dated 2025-04-16T14:24:50.000Z thumbnail image

Stay in the know with updates to Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.